# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
See Stanley Druckenmiller's Q2 13F filing. Duquesne adds Microsoft and big banks, cuts Coupang, and makes a bullish bet on ...
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commi...
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for...
Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Neutral and maintains $47 price ...
HC Wainwright & Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lower...
Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lowers...
TD Cowen analyst Yaron Werber downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Hold and lowers the price target...